Semi-Euglucon en es it fr

Semi-Euglucon Brand names, Semi-Euglucon Analogs

Semi-Euglucon Brand Names Mixture

  • No information avaliable

Semi-Euglucon Chemical_Formula

C23H28ClN3O5S

Semi-Euglucon RX_link

http://www.rxlist.com/cgi/generic/glybur.htm

Semi-Euglucon fda sheet

Semi-Euglucon msds (material safety sheet)

Semi-Euglucon MSDS

Semi-Euglucon Synthesis Reference

Weber et al., U.S. Pat. 3,454,635 (1969)

Semi-Euglucon Molecular Weight

494.004 g/mol

Semi-Euglucon Melting Point

169-170oC

Semi-Euglucon H2O Solubility

4 mg/L

Semi-Euglucon State

Solid

Semi-Euglucon LogP

4.85

Semi-Euglucon Dosage Forms

Tablet (1.25 mg, 2.5 mg, 5 mg)

Semi-Euglucon Indication

Indicated as an adjunct to diet to lower the blood glucose in patients with non-insulin-dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.

Semi-Euglucon Pharmacology

Glyburide, a second-generation sulfonylurea antidiabetic agent, appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonyl-urea hypoglycemic drugs. The combination of glyburide and metformin may have a synergistic effect, since both agents act to improve glucose tolerance by different but complementary mechanisms. In addition to its blood glucose lowering actions, glyburide produces a mild diuresis by enhancement of renal free water clearance. Glyburide is twice as potent as the related second-generation agent glipizide.

Semi-Euglucon Absorption

Significant absorption within 1 hour and peak plasma levels are reached within 4 hours.

Semi-Euglucon side effects and Toxicity

Oral rat LD50: > 20,000 mg/kg. Oral mouse LD50: 3250 mg/kg.

Semi-Euglucon Patient Information

Patients should be informed of the potential risks and advantages of MICRONASE and of alternative modes of therapy. They also should be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of urine and/or blood glucose.

The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members. Primary and secondary failure also should be explained.

Semi-Euglucon Organisms Affected

Humans and other mammals